Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMB Reversal in Cardiac Surgery
NCT03574337Phase 4Withdrawn
- Sponsor
- Henry Ford Health
- Start
- Aug 2018
- Primary completion
- Aug 2018
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Henry Ford Health. Planned start Aug 2018; status: withdrawn.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03574337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03574337.